These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038 [TBL] [Abstract][Full Text] [Related]
4. Theranostic nanoparticles for detection and treatment of pancreatic cancer. Agarwal H; Bynum RC; Saleh N; Harris D; MacCuaig WM; Kim V; Sanderson EJ; Dennahy IS; Singh R; Behkam B; Gomez-Gutierrez JG; Jain A; Edil BH; McNally LR Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(4):e1983. PubMed ID: 39140128 [TBL] [Abstract][Full Text] [Related]
5. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Liu H; Shi Y; Qian F Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881 [TBL] [Abstract][Full Text] [Related]
6. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival. Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927 [TBL] [Abstract][Full Text] [Related]
7. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257 [TBL] [Abstract][Full Text] [Related]
8. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma. Song H; Jiang C Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832 [TBL] [Abstract][Full Text] [Related]
10. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming. Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402 [TBL] [Abstract][Full Text] [Related]
11. Novel systemic treatment approaches for metastatic pancreatic cancer. Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868 [TBL] [Abstract][Full Text] [Related]
12. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity. Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447 [TBL] [Abstract][Full Text] [Related]
13. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon? Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367 [TBL] [Abstract][Full Text] [Related]
14. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies. Wang Z; Wu B; Nie G; Wei J; Li Y Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836 [TBL] [Abstract][Full Text] [Related]
15. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Chen X; Zhou W; Liang C; Shi S; Yu X; Chen Q; Sun T; Lu Y; Zhang Y; Guo Q; Li C; Zhang Y; Jiang C Nano Lett; 2019 Jun; 19(6):3527-3534. PubMed ID: 31058513 [TBL] [Abstract][Full Text] [Related]
16. Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma. West DL; White SB; Zhang Z; Larson AC; Omary RA Int J Nanomedicine; 2014; 9():4169-76. PubMed ID: 25214781 [TBL] [Abstract][Full Text] [Related]
17. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134 [TBL] [Abstract][Full Text] [Related]
18. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma. Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U Front Immunol; 2024; 15():1323198. PubMed ID: 38384463 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. Natu J; Nagaraju GP Cancer Lett; 2023 Oct; 573():216382. PubMed ID: 37666293 [TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities. Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]